| Dr Nkechinyere A Nwaobasi, MD | |
|
3001 Hospital Dr, Cheverly, MD 20785-1189 | |
| (301) 618-3986 | |
| Not Available |
| Full Name | Dr Nkechinyere A Nwaobasi |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 16 Years |
| Location | 3001 Hospital Dr, Cheverly, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346497047 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D0074860 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dimensions Healthcare Associates Inc | 1557269743 | 103 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Dimensions Healthcare Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346354834 PECOS PAC ID: 1557269743 Enrollment ID: O20031226000032 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Professional Services Of Holy Cross |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487692828 PECOS PAC ID: 3779516992 Enrollment ID: O20050916000745 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nkechinyere A Nwaobasi, MD 3001 Hospital Dr, Cheverly, MD 20785-1189 Ph: (301) 618-3986 | Dr Nkechinyere A Nwaobasi, MD 3001 Hospital Dr, Cheverly, MD 20785-1189 Ph: (301) 618-3986 |
News Archive
Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
A home-based telehealth system being pushed by the UK Government does not benefit patients with long-term conditions in terms of their quality of life or psychologic wellbeing, research has shown.
Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").
› Verified 2 days ago
Karyn E White, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3001 Hospital Dr, Perinatal Diagnostic Center, Cheverly, MD 20785 Phone: 301-618-3542 Fax: 301-618-3374 | |
Charles John Akoda, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6005 Landover Road, Suite 5, Cheverly, MD 20785 Phone: 301-322-2127 Fax: 301-322-9770 |